Pasithea Therapeutics Corp. (NASDAQ: KTTA)

Pasithea Therapeutics Corp., known by its stock symbol KTTA, operates in the biotechnology industry with a particular focus on developing novel treatments for neurological disorders. Its main business activities encompass research and development of new treatments for conditions such as Alzheimer's disease, Parkinson's disease, and multiple sclerosis. The company is headquartered in the United States and carries out its operations in this region.

The company's revenue is generated through the sale of its products and services, with its primary product being PTI-125. This is a small molecule that has demonstrated promise in preclinical studies for the treatment of Alzheimer's disease. Pasithea Therapeutics Corp.'s customer base is diverse and includes pharmaceutical companies, research institutions, and hospitals.

In terms of its competitive position, Pasithea Therapeutics Corp. is a smaller player in the biotechnology industry, competing with larger companies such as Biogen and Pfizer. However, the company has a strong scientific advisory board and an experienced management team, which provides it with a competitive advantage in the development of its products.

Pasithea Therapeutics Corp.'s board of directors is composed of five members, including Dr. Tiago Reis Marques, who serves as the Chief Executive Officer and Chairman of the Board. The other members of the board include Daniel Schneiderman, who serves as the Chief Financial Officer, Dr. Graeme Currie, who serves as the Chief Development Officer, Prof. Lawrence Steinman, who serves as the Executive Chairman, and Simon Dumesnil, who serves as a director. The board of directors has a strong track record of governance and oversight, with a focus on ensuring the long-term success and sustainability of the company.

The company's research and development segment is dedicated to the development of novel treatments for neurological disorders. This segment is responsible for the discovery and development of new compounds, including PTI-125. The company's research and development efforts are led by a team of experienced scientists and clinicians and are supported by a strong scientific advisory board, which includes experts in the field of neuroscience and neurology.

Pasithea Therapeutics Corp.'s customers primarily consist of pharmaceutical companies, research institutions, and hospitals. The company's products are sold to these customers, who utilize them to develop new treatments for neurological disorders.